Yao X - Search Results

1

Comparison of HPV neutralizing and IgG antibodies in unvaccinated female adolescents.

Yao X, Chu K, Zhao J, Hu Y, Lin Z, Lin B, Chen Q, Li Y, Zhang Q, Fang M, Huang S, Wang Y, Su Y, Wu T, Zhang J, Xia N. Yao X, et al. Future Microbiol. 2022 Oct;17:1207-1215. doi: 10.2217/fmb-2021-0221. Epub 2022 Jul 29. Future Microbiol. 2022. PMID: 35905119

2

Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study.

Wei F, Su Y, Yao X, Cui X, Bian L, Yin K, Yu X, Zhuang C, Bi Z, Huang S, Li M, Wu T, Xia N, Zhang J. Wei F, et al. Among authors: yao x. Int J Cancer. 2019 Aug 1;145(3):807-816. doi: 10.1002/ijc.32255. Epub 2019 Mar 22. Int J Cancer. 2019. PMID: 30848495 Free article.

3

Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women.

Hu YM, Guo M, Li CG, Chu K, He WG, Zhang J, Gu JX, Li J, Zhao H, Wu XH, Lin B, Lin ZJ, Yao XM, Li YF, Wei F, Huang Y, Su YY, Zhu FC, Huang SJ, Pan HR, Wu T, Zhang J, Xia NS. Hu YM, et al. Sci China Life Sci. 2020 Apr;63(4):582-591. doi: 10.1007/s11427-019-9547-7. Epub 2019 Jun 21. Sci China Life Sci. 2020. PMID: 31231780 Free PMC article.

4

Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages.

Chen Q, Zhao H, Yao X, Lin Z, Li J, Lin B, Wang R, Huang Y, Su Y, Wu T, Li C, Pan H, Huang S, Zhang J, Xia N. Chen Q, et al. Among authors: yao x. Vaccine. 2020 Sep 3;38(39):6096-6102. doi: 10.1016/j.vaccine.2020.07.030. Epub 2020 Jul 24. Vaccine. 2020. PMID: 32718817

5

Maternal CMV seroprevalence rate in early gestation and congenital cytomegalovirus infection in a Chinese population.

Huang Y, Li T, Yu H, Tang J, Song Q, Guo X, Wang H, Li C, Wang J, Liang C, Yao X, Qiu L, Zhuang C, Bi Z, Su Y, Wu T, Ge S, Zhang J. Huang Y, et al. Among authors: yao x. Emerg Microbes Infect. 2021 Dec;10(1):1824-1831. doi: 10.1080/22221751.2021.1969290. Emerg Microbes Infect. 2021. PMID: 34392819 Free PMC article.

6

Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study.

Yao X, Chen W, Zhao C, Wei L, Hu Y, Li M, Lin Z, Lin B, Liu X, Hong Y, Li Q, Pan Q, Zhang X, Li M, Zhao Y, Zhang L, Xu H, Hu F, Zhao J, Huang Y, Sheng W, Zheng Y, Hu S, Su Y, Huang S, Pan H, Zhao F, Qiao Y, Wu T, Zhang J, Xia N. Yao X, et al. Lancet Reg Health West Pac. 2021 Jul 16;13:100196. doi: 10.1016/j.lanwpc.2021.100196. eCollection 2021 Aug. Lancet Reg Health West Pac. 2021. PMID: 34527987 Free PMC article.

7

The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.

Chen Q, Zhu K, Liu X, Zhuang C, Huang X, Huang Y, Yao X, Quan J, Lin H, Huang S, Su Y, Wu T, Zhang J, Xia N. Chen Q, et al. Among authors: yao x. Emerg Microbes Infect. 2022 Dec;11(1):793-803. doi: 10.1080/22221751.2022.2046446. Emerg Microbes Infect. 2022. PMID: 35195494 Free PMC article.

8

Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.

Huang ZH, Lu GY, Qiu LX, Zhong GH, Huang Y, Yao XM, Liu XH, Huang SJ, Wu T, Yuan Q, Wang YB, Su YY, Zhang J, Xia NS. Huang ZH, et al. BMC Cancer. 2022 Mar 17;22(1):287. doi: 10.1186/s12885-022-09413-7. BMC Cancer. 2022. PMID: 35300634 Free PMC article.

9

Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls.

Yao X, He W, Wu X, Gu J, Zhang J, Lin B, Bi Z, Su Y, Huang S, Hu Y, Wu T, Zhang J, Xia N. Yao X, et al. Hum Vaccin Immunother. 2022 Nov 30;18(5):2061248. doi: 10.1080/21645515.2022.2061248. Epub 2022 Apr 13. Hum Vaccin Immunother. 2022. PMID: 35417301 Free PMC article. Clinical Trial.

10

Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.

Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J, Qiao YL, Xia NS. Zhao FH, et al. Among authors: yao xm. Lancet Infect Dis. 2022 Dec;22(12):1756-1768. doi: 10.1016/S1473-3099(22)00435-2. Epub 2022 Aug 26. Lancet Infect Dis. 2022. PMID: 36037823 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10,506 results

Search Page